Pacific Biosciences of California Stock News

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover. But while the Tesla (NASDAQ: TSLA) chieftain’s $54.20 per share bid for Twitter (NYSE: TWTR) con

Anyone thinking about buying shares should know them, too.

PacBio shares have been hit hard as investors have abandoned riskier high-multiple life sciences stocks, and weaker guidance for FY'22 certainly didn't help.

Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology Science magazine publication details how the human genome was finally compl

Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region

LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

During the last session, Pacific Biosciences of California Inc. (NASDAQ:PACB)’s traded shares were 2.28 million, with the beta value of the company hitting 1.33. At the end of the trading day, the stock’s price was $10.94, reflecting an intraday loss of -2.58% or -$0.29. The 52-week high for the PACB share is $37.42, that puts … Does Pacific Biosciences of California Inc. (NASDAQ: PACB) Still Look Attractive After A -3.19% Selloff Last Week? Read More »

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

WASHINGTON, March 07, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Genomics in Cancer Care Market finds that rising demand for technologically advanced & cost-efficient diagnostic technology and increasing demand for diagnostics centres are augmenting the growth of Genomics in Cancer Care Market in upcoming years. In addition, growing research activities for the development of novel treatment therapies and increasing funding for the development of pharmaceutical and biotech industry are some other important parameters that bolstering the market demand in the projected time span. The total Global Genomics in Cancer Care Market is estimated to reach USD 40.5 Billion by 2028. The market stood at a revenue of USD 12.1 Billion in the year 2021, and expected to grow at a Compound Annual Growth Rate (CAGR) of 16.1%, states Vantage Market Research, in a report, titled " Genomics in Cancer Care Market by Product (Instruments, Consumables, Services), by Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), by Technology (Genome Sequencing, PCR, Microarrays, Nucleic Acid Extraction & Purification), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee